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What’s the uptake? Pragmatic RCTs may be
used to estimate uptake, and thereby
population impact of interventions, but
better reporting of trial recruitment
processes is needed
Katy J. L. Bell1,2*, Amanda McCullough2, Chris Del Mar2 and Paul Glasziou2
Abstract
Background: Effectiveness of interventions in pragmatic trials may not translate directly into population impact,
because of limited uptake by clinicians and/or the public. Uptake of an intervention is influenced by a number of
factors.
Methods: We propose a method for calculating population impact of clinical interventions that accounts for the
intervention uptake. We suggest that population impact may be estimated by multiplying the two key
components: (1) the effectiveness of the intervention in pragmatic trials (trial effect); and, (2) its uptake in clinical
practice. We argue that participation rates in trials may be a valid proxy for uptake in clinical practice and, in
combination with trial effectiveness estimates, be used to rank interventions by their likely population impact. We
illustrate the method using the example of four interventions to decrease antibiotic prescription for acute
respiratory infections in primary care: delayed prescribing, procalcitonin test, C-Reactive Protein, shared decision
making.
Results: In order to estimate uptake of interventions from trial data we need detailed reporting on the recruitment
processes used for clinician participation in the trials. In the antibiotic prescribing example, between 75 and 91% of
the population would still be prescribed or consume antibiotics because effective interventions were not taken up.
Of the four interventions considered, we found that delayed prescribing would have the highest population impact
and shared decision making the lowest.
Conclusion: Estimates of uptake and population impact of an intervention may be possible from pragmatic RCTs,
provided the recruitment processes for these trials are adequately reported (which currently few of them are).
Further validation of this method using empirical data on intervention uptake in the real world would support use
of this method to decide on public funding of interventions.
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microbial
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Background
The effectiveness of an intervention in real clinical prac-
tice may be estimated in pragmatic trials conducted on
patients who represent the full spectrum of the popula-
tion to which the intervention might be applied, and
where the comparator group receives usual care [1, 2].
Pragmatic trials are designed to determine the effects of
an intervention under the usual conditions in which it
will be applied, [3] and focus on the choice between op-
tions for care rather than biological understanding [4].
They may be contrasted to explanatory trials designed to
determine the effects of an intervention under the ideal
conditions, [5] in order to test causal research hypoth-
eses, such as whether the intervention causes a particu-
lar biological effect [4]. Tools have been developed to
help trialists with design decisions on how pragmatic or
explanatory they wish their trial to be, [5, 6] and an ex-
tension of the CONSORT statement guides the reporting
of pragmatic trials [7].
Estimates of intervention effectiveness may then be
made using an intention to treat analysis of outcomes in
the intervention group compared to those in the usual
care group (‘trial effectiveness’) [7]. That is, patients are
analysed in the group to which they were initially rando-
mised, even if they drop out of the study or change
groups [8]. But within trial effectiveness do not translate
directly into population impact [9]. One important dif-
ference is uptake by clinicians and/or the public [10].
For example, for the long-term follow-up after colorectal
cancer treatment, colonoscopy is the most sensitive
method. But the less sensitive faecal occult blood testing
has greater population impact because patients are will-
ing to complete the four rounds of testing – that is, it
has higher uptake [11]. Uptake of an intervention is influ-
enced by a number of factors; for example for clinician
uptake, these range from knowledge of the intervention
and the skills to implement it, through to emotion regula-
tion and beliefs about the intervention itself [12].
In this paper, we propose a method for calculating
population impact of clinical interventions that accounts
for the intervention uptake. We suggest that population
impact may be estimated by multiplying the two key
components: (1) the effectiveness of the intervention in
pragmatic trials; and, (2) its uptake in clinical practice.
That is,
population impact = trial effectiveness x rate of uptake.
Obtaining the trial effectiveness is straightforward
from either primary pragmatic randomised controlled
trials (RCTs) or meta-analyses of pragmatic RCTs. How-
ever, obtaining the uptake of an intervention by clini-
cians is more difficult. The best estimates come from
studies measuring this directly (such as surveys of clini-
cians or patients), but these are rare [13]. An alternative
indirect approach is to use data derived from the
recruitment process of relevant pragmatic RCTs. Below,
we illustrate how this can answer the following question
relevant to a public health problem:
“What intervention to minimise antibiotic prescribing
for acute respiratory infections in primary care is likely
to have the largest effect at a population-level?”
Example using RCTS to estimate population
effectiveness
Interventions to minimise antibiotic prescriptions for
acute respiratory infections in primary care.
Method
Meta-analyses of pragmatic trials show that 4 interven-
tions reduce antibiotic prescribing and/or consumption
for acute respiratory infections in primary care:
 Delayed prescribing,
 Procalcitonin test
 C-Reactive Protein,
 Shared decision making
We calculated the population impact of each interven-
tion using a 3-step process:
First, we extracted the meta-analytic estimates of the
trial effectiveness of the interventions (two extractors).
Where these were not presented in the original meta-
analysis, we undertook new analyses in RevMan 5.3 [14]
to obtain relative risks (with random effects models) and
confidence intervals.
Second, we calculated the rate of uptake. From each sys-
tematic review we identified pragmatic RCTs that reported
the number of clinicians invited to particpate, and those
who did participate. We calculated the uptake by dividing
the number of GPs who participated by those invited.
Where this was reported for both GP practices, and GPs
within participating practices, we calculated uptake by
multiplying the two proportions. We excluded RCTs from
this analysis that did not have a population based recruit-
ment (e.g. only invited academic GPs attached to a Uni-
versity department). Where there was more than one
RCT for estimating the uptake, we estimated the mean up-
take rate and confidence intervals using a logistic regres-
sion model with random intercepts, using PROC
NLMIXED in SAS software, version 9.4 [15]. Where there
was only one RCT, we calculated confidence intervals for
a single proportion using the binomial distribution.
Finally, we calculated population impact of the interven-
tion by multiplying the trial effectiveness by the uptake.
Results
Table 1 summarises the 4 included systematic reviews
that provided estimates of trial effectiveness and the 6
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pragmatic RCTS (1 for delayed prescribing [16], 1 for
procalcitonin [17], 1 for C-reactive protein [CRP] [18],
and 3 for shared decision making [19–21]) that provided
estimates of uptake. All reviews were on patients with
acute respiratory infections, and the RCTs were con-
ducted across several countries including Denmark,
Germany and Canada. The RCTs were all primarily of
pragmatic type, with high applicability to the actual clin-
ical settings the intervention was intended to be used,
and a very good match between the trial usual care arm
and the intended primary care population [6].
Delayed prescribing had the highest trial effectiveness
(relative risk reduction [RRR] of 64% in antibiotic con-
sumption) and CRP the lowest (RRR 22% in antibiotics
prescribed) (Table 2). New meta-analytic estimates were
calculated for procalcitonin (RRR 61%) and delayed pre-
scribing (RRR 64%). There was substantial heterogeneity
between studies for both of these interventions (RRR
range 42–74% for procalcitonin and 42–79% for delayed
prescribing).
In contrast, CRP had the highest uptake rate (28%)
and shared decision making the lowest (10%) (Table 2),
meaning that between 72 and 90% of clinicians invited
to participate did not wish to use these interventions.
(We pooled data from 3 RCTS to estimate population
uptake for shared decision making, and used data from
1 RCT to estimate uptake for the other 3 interventions).
Delayed prescribing had the highest population impact
at 12% and shared decision making the lowest (4%) (Table
2, Fig. 1). For delayed prescribing, this means that if im-
plemented, in 12% of clinical encounters where a person
with an acute respiratory infection would otherwise have
been prescribed antibiotics, the doctor would use (uptake)
the intervention and the patient would not consume anti-
biotics (Table 2, Fig. 1), in 7% the doctor would use the
intervention but the patient would still consume antibi-
otics, and in 81% the doctor would not use the intervention
and the patient would consume antibiotics.
The most notable finding is that the greatest con-
straint to population impact is the poor uptake of inter-
ventions by clinicians rather than the effectiveness of the
interventions themselves. Between 72 and 91% of the
population would still be prescribed or consume antibi-
otics because effective interventions have not been taken
up, Fig. 1. Of the four potential interventions shown to
decrease antibiotic prescribing in RCTs, delayed pre-
scribing is the intervention with the highest population
impact, and could prove the best choice for
implementation.
Challenges to this method
Better reporting of trial recruitment is needed
The poor reporting of both the uptake by clinicians, and
of the methods of recruitment, limit our ability to
Table 1 Characteristics of included systematic reviews for estimating trial effectiveness, and of RCTs for estimating uptake, of
interventions to decrease antibiotic prescription for acute respiratory infections in primary care
Systematic Reviews used for estimating
trial effectiveness
Pragmatic RCTs used for estimating uptake
Intervention Clinical population Outcome Clinical population Recruitment of clinicians
Delayed
prescribing
[25]
People patients of all ages with
upper respiratory tract infection
Antibiotic use (i.e.
prescriptions filled)
Adults with acute cough, for
whom the physician intended to
prescribe antibiotics [16]
22/61 practices approached
actually participated. 48/92 GPs
recruited patients to the trial
(range = 1–25 per GP).
Procalcitonin
[26]
Adults with an acute respiratory
infection (including lower
respiratory infection such as
pneumonia).
Antibiotics prescribed Adults with an acute respiratory
infection, for whom the physician
intended to prescribe antibiotics
[17]
53/345 eligible primary care
physicians in 2 cantons in
northwest Switzerland actually
participated
CRP [27] People of all ages with acute
respiratory infection (including
lower respiratory infection such as
pneumonia)
Antibiotics prescribed People of all ages with respiratory
Infections (median age
= 37 years [18])
35/125 GPs in single-handed
practices in the County of Funen
actually participated
Shared
decision
making [28]
People of all ages with acute
respiratory infection (including
lower respiratory infection such as
pneumonia)
Antibiotics prescribed,
dispensed or decision to
use
Adults with acute respiratory
infection. [19]
45/345 eligible GPs in two
cantons, Basel-Stadt and Aargau
actually participated.
People of all ages with acute
cough (mean age
= 42 years [20]
101/2036 GPs from 9 regions in
North-Rhine and Westphalia-
Lippe actually participated
People of all ages with respiratory
Infections (71% adults) [21]
4/24 Family Medicine Groups
(FMGs) in Quebec actually
participated.
Within the participating FMGs,
33/42 FPs participated
CRP C-Reactive Protein, GP General Practitioner, FMG Family Medicine Group, FP Family Practitioner
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estimate overall impact and hence inform health policy.
In the antibiotic prescribing example, only some trials
reported the number of general practices randomised
out of those approached, and only a few reported on the
number of clinicians who then participated out of the
total eligible within each practice. No trials reported on
the number of patients randomised out of the total
number of eligible patients seen by each of the partici-
pating GPs.
Better reporting of both recruitment rates and recruit-
ment methods are crucial to new RCTs. The extended
CONSORT checklist [6] and flow diagram requires
reporting of eligibility criteria to show the degree to
which they include typical participants and/or typical
providers, institutions, communities and settings of care,
and the number of participants or units approached to
take part in the trial, the number which were eligible,
and reasons for non-participation [22]. We recommend
that criteria be added to this to include reporting on the
methods of recruitment, including the dialogue and in-
centives, and the resulting recruitment rates. In this way,
we can utilise data which are routinely collected in prag-
matic trials but not currently publicly available, helping
to reduce waste in research [23]. Just as estimates of trial
effectiveness may be context-dependent, so too may be
the trial estimates of uptake, and results may not be eas-
ily translated across different settings. Ideally, estimates
of uptake should be based on meta-analysis of multiple
trials of the intervention, with exploration of heterogen-
eity between trials to identify potential facilitators and
barriers of intervention uptake. This would allow esti-
mates of population impact under best case and worse
case scenarios as well as helping inform implementation
strategies. The actual population impact may be lower
than in these scenarios, as even when the clinician and
patient decide to uptake the intervention, they are gen-
erally less adherent to this in real life than in the trial
setting (and so the trial effectiveness overestimates the
real life effectiveness).
Does uptake in RCTs predict uptake in clinical practice?
The uptake reported in pragmatic RCTs may be either
under- or over-estimates: the additional perceived bur-
den of the research element in RCTs may lead us to
underestimate uptake; however, the extra support pro-
vided in the research setting may result in overestimates
of uptake in the real world. These biases may favour one
intervention over another. A further issue is that the
willingness of clinicians to participate in pragmatic trials
where the effectiveness of an intervention is unknown,
may be different to the uptake in clinical practice when
effectiveness has been established. For instance, inter-
ventions that have been shown to be effective may be
promoted or even mandated in ways which would affect
participation in practice. However, in the early pre-
implementation stage where we are suggesting the
method may be used to inform funding decisions (i.e.
after the completion of the trials, but before a decision
to publically fund and/or promote the intervention has
been made), these considerations may not be as
important.
Validation of our method may be possible for interven-
tions that have previously received public funding. For
example, a large prospective cohort study found that
14% of UK based general practitioners used delayed pre-
scribing of antibiotics for adults presenting with a sore
throat [13] – this is not dissimilar to our estimated up-
take rate of 19% (95% CI 14–24%). We could not find
population based studies on uptake of the other three
interventions in clinical populations similar to those in
Fig. 1 Estimated population impact for four interventions that aim to reduce antibiotic use for acute respiratory infections. Estimates are for a
patient population who would be prescribed antibiotics in absence of intervention
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trials. One nationwide cross-sectional study found that
70% of Norwegian GPs used CRP for children aged
5 years or under who presented with a respiratory infec-
tion [24], but use of CRP for adult patients is not known.
We estimated that CRP had an uptake rate of 28% (95%
CI 20–36%) for use in adults, and although this was the
highest uptake out of the 4 interventions we studied, it
may still be an underestimate. Prospective evaluation as
part of implementation trials could also help us work
out if our uptake estimates are reflective of “real-life” up-
take rates. If such comparisons support the use of our
method for ranking interventions on their likely uptake
in clinical practice, then this method might also be used
to decide on public funding of interventions at the
outset.
Conclusions
For estimating the population impact of interventions,
knowing the uptake rate may be as important as the trial
effectiveness, but is not usually considered when decid-
ing on public funding. Estimates of uptake may be pos-
sible from pragmatic RCTs of the intervention, provided
the recruitment processes for these trials are adequately
reported (which currently few of them are).
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